Long-term survival after hepatic and pulmonary resection of colorectal cancer metastases

2013 ◽  
Vol 108 (4) ◽  
pp. 220-224 ◽  
Author(s):  
Isabelle Sourrouille ◽  
Pierre Mordant ◽  
Léon Maggiori ◽  
Safi Dokmak ◽  
Guy Lesèche ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Pulmonary Resection ◽  
Term Survival ◽  
Long Term Survival ◽  
Cancer Metastases ◽  
Colorectal Cancer Metastases

New Trends in the Surgical Treatment of Colorectal Cancer Liver Metastases

1998 ◽  
Vol 84 (3) ◽  
pp. 281-288 ◽  
Author(s):  
Steven A. Curley ◽  
Rosario Vecchio
Keyword(s):  
Colorectal Cancer ◽  
Surgical Treatment ◽  
Liver Resection ◽  
Liver Metastases ◽  
Colorectal Cancer Liver Metastases ◽  
Term Survival ◽  
Long Term Survival ◽  
Cancer Metastases ◽  
Colorectal Cancer Metastases

Colorectal cancer is one of the most common solid tumors affecting people around the world. A significant proportion of patients with colorectal cancer will develop or will present with liver metastases. In some of these patients, the liver is the only site of metastatic disease. Thus, surgical treatment approaches are an appropriate and important treatment option in patients with liver-only colorectal cancer metastases. Resection of colorectal cancer liver metastases can produce long-term survival in selected patients, but the efficacy of liver resection as a solitary treatment is limited by two factors. First, a minority of patients with liver metastases have resectable disease. Second, the majority of patients who undergo successful liver resection for colorectal cancer metastases develop recurrent disease in the liver, extrahepatic sites, or both. In this paper, in addition to the results of liver resection for colorectal cancer metastases, we will review the results of cryoablation, heat ablation, and hepatic arterial chemotherapy using a surgically implanted pump. Each of these surgical treatment modalities can produce long-term survival in a subset of patients with liver-only colorectal cancer metastases, whereas systemic chemotherapy used alone rarely results in long-term survival in these patients. While surgical treatments provide the best chance for long-term survival or, in some cases, the best palliation in patients with colorectal cancer liver metastases, it is clear that further improvements in patient outcome will require multimodality therapy regimens.

Analysis of Prognostic Factors Influencing Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer

2007 ◽  
Vol 32 (1) ◽  
pp. 93-103 ◽  
Author(s):  
Marcella Arru ◽  
Luca Aldrighetti ◽  
Renato Castoldi ◽  
Saverio Di Palo ◽  
Elena Orsenigo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Hepatic Resection ◽  
Metastatic Colorectal Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Factors Influencing

scholarly journals Comparison of Long-term outcomes between Lynch sydrome and sporadic colorectal cancer: a propensity score matching analysis

2020 ◽  
Author(s):  
Yun Xu ◽  
Cong Li ◽  
Charlie Zhi-Lin Zheng ◽  
Yu-Qin Zhang ◽  
Tian-An Guo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Control Group ◽  
Sporadic Colorectal Cancer ◽  
Long Term Outcomes ◽  
Term Survival ◽  
Long Term Survival ◽  
Tumor Stages

Abstract Background Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome. Comparison of prognosis between LS and sporadic CRC (SCRC) were rare,with conflicting results. This study aimed to compare the long-term outcomes between patients with LS and SCRC. Methods Between June 2008 and September 2018, a total of 47 patients were diagnosed with LS by genetic testing at Fudan University Shanghai Cancer Center. A 1:2 propensity score matching was performed to obtain homogeneous cohorts from SCRC group. Thereafter, 94 SCRC patients were enrolled as control group. The long-term survival rates between the two groups were compared, and the prognostic factors were also analyzed. Results The 5-year OS rate of LS group was 97.6%, which was significantly higher than of 82.6% for SCRC group (p = 0.029). The 5-year PFS rate showed no significant differences between the two groups (78.0% for LS group vs. 70.6% for SCRC patients; p = 0.262). The 5-year TFS rates in LS group was 62.1% for LS patients, which were significantly lower than of 70.6% for SCRC group (p = 0.039). By multivariate analysis, we found that tumor progression of primary CRC and TNM staging were independent risk factors for OS. Conclusion LS patients have better long-term survival prognosis than SCRC patients. Strict regular follow-up monitoring, detection at earlier tumor stages, and effective treatment are key to ensuring better long-term prognosis.

Sign in / Sign up

Export Citation Format

Share Document